RESUMEN
BACKGROUND: Asthma, and severe asthma in particular, is often managed within a specialized field with allergists and clinical immunologists playing a leading role. In this respect, the National Scientific Society SIAAIC (Società Italiana di Allergologia, Asma ed Immunologia Clinica), structured in Regional and Inter-Regional sections, interviewed a large number of specialists involved in the management of this respiratory disease. METHODS: A survey entitled "Management of patients with asthma and severe asthma" based on 17 questions was conducted through the SIAAIC newsletter in 2019 thanks to the collaboration between GlaxoSmithKline S.p.A. and the Inter-Regional Section of SIAAIC of Central Italy. RESULTS: Fifty-nine allergists and clinical immunologists participated to the survey, and 40 of them completed the entire questionnaire. Almost all of the specialists (88%) reported that asthma control was achieved in above 50% of their patients, even if only one third (32%) actually used validated clinical tools such as asthma control test (ACT). Poor adherence to inhaled therapy was recognized as the main cause of asthma control failure by 60% of respondents, and 2-5 min on average is dedicated to the patient inhaler technique training by two-thirds of the experts (65%). Maintenance and as-needed therapy (SMART/MART) is considered an appropriate approach in only a minority of the patients (25%) by one half of the respondents (52%). A high number of exacerbations despite the maximum inhalation therapy were recognized as highly suspicious of severe asthma. Patients eligible for biological therapies are 3-5% of the patients, and almost all the responders (95%) agreed that patients affected by severe asthma need to be managed in specialized centers with dedicated settings. Biological drugs are generally prescribed after 3-6 months from the initial access to the center, and once started, the follow-up is initially programmed monthly, and then every 3-6 months after the first year of treatment (96% of responders). After phenotyping and severity assessment, comorbidities (urticaria, chronic rhinosinusitis with or without nasal polyps, vasculitis, etc.) are the drivers of choice among the different biological drugs. In the management of severe asthma, general practitioners (GPs) should play a central role in selecting patients and referring them to specialized centers while Scientific Societies should train GPs to appropriately recognize difficult asthma and promote public disease awareness campaigns. CONCLUSIONS: This survey which collects the point of view of allergists and clinical immunologists from Central Italy highlights that asthma control is still not measured with validated instruments. There is a general consensus that severe asthma should be managed only in dedicated centers and to this aim it is essential to encourage patient selection from a primary care setting and develop disease awareness campaigns for patients.
RESUMEN
Recently, a strong correlation between metabolic disorders, tumor onset, and progression has been demonstrated, directing new therapeutic strategies on metabolic targets. OLR1 gene encodes the LOX-1 receptor protein, responsible for the recognition, binding, and internalization of ox-LDL. In the past, several studied, aimed to clarify the role of LOX-1 receptor in atherosclerosis, shed light on its role in the stimulation of the expression of adhesion molecules, pro-inflammatory signaling pathways, and pro-angiogenic proteins, including NF-kB and VEGF, in vascular endothelial cells and macrophages. In recent years, LOX-1 upregulation in different tumors evidenced its involvement in cancer onset, progression and metastasis. In this review, we outline the role of LOX-1 in tumor spreading and metastasis, evidencing its function in VEGF induction, HIF-1alpha activation, and MMP-9/MMP-2 expression, pushing up the neoangiogenic and the epithelial-mesenchymal transition process in glioblastoma, osteosarcoma prostate, colon, breast, lung, and pancreatic tumors. Moreover, our studies contributed to evidence its role in interacting with WNT/APC/ß-catenin axis, highlighting new pathways in sporadic colon cancer onset. The application of volatilome analysis in high expressing LOX-1 tumor-bearing mice correlates with the tumor evolution, suggesting a closed link between LOX-1 upregulation and metabolic changes in individual volatile compounds and thus providing a viable method for a simple, non-invasive alternative monitoring of tumor progression. These findings underline the role of LOX-1 as regulator of tumor progression, migration, invasion, metastasis formation, and tumor-related neo-angiogenesis, proposing this receptor as a promising therapeutic target and thus enhancing current antineoplastic strategies.
Asunto(s)
Biomarcadores de Tumor/metabolismo , Neoplasias/genética , Receptores Depuradores de Clase E/metabolismo , Animales , Línea Celular Tumoral , Humanos , Masculino , RatonesRESUMEN
BACKGROUND: Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. OBJECTIVE: To assess dupilumab effectiveness and safety in adults with moderate-to-severe AD in a real-life Italian multicentre retrospective cohort. METHODS: Adult moderate-to-severe AD patients, referring to 39 Italian centers, received dupilumab in the context of a national patient access program. Disease assessment was performed at baseline, after 4 and 16 weeks of treatment using Eczema-Area-and-Severity-Index (EASI) score, itch and sleep numerical-rating-score (itch-NRS, sleep-NRS) and Dermatology-Life-Quality-Index (DLQI). RESULTS: A total of 109 (71 M/38F) patients was studied. There was a significant reduction in EASI score, itch-NRS, sleep-NRS and DLQI from baseline to week 4 and a further significant decline to week 16. EASI 50, EASI75 and EASI90 were achieved by 59.6%, 28.4% and 9.3% of patients at 4 weeks and by 87.2%, 60.6% and 32.4% of them at 16 weeks, respectively. Adverse events were experienced by 19.2% (21/109) of the patients and they were all mild in intensity, being conjunctivitis the most common side effect. CONCLUSIONS: Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile.
Asunto(s)
Anticuerpos Monoclonales Humanizados/administración & dosificación , Dermatitis Atópica/tratamiento farmacológico , Prurito , Calidad de Vida , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Femenino , Humanos , Masculino , Persona de Mediana Edad , Prurito/tratamiento farmacológico , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Sueño , Resultado del Tratamiento , Adulto JovenRESUMEN
We provide a database of the surface ruptures produced by the 26 December 2018 Mw 4.9 earthquake that struck the eastern flank of Mt. Etna volcano in Sicily (southern Italy). Despite its relatively small magnitude, this shallow earthquake caused about 8 km of surface faulting, along the trace of the NNW-trending active Fiandaca Fault. Detailed field surveys have been performed in the epicentral area to map the ruptures and to characterize their kinematics. The surface ruptures show a dominant right-oblique sense of displacement with an average slip of about 0.09 m and a maximum value of 0.35 m. We have parsed and organized all observations in a concise database, with 932 homogeneous georeferenced records. The Fiandaca Fault is part of the complex active Timpe faults system affecting the eastern flank of Etna, and its seismic history indicates a prominent surface-faulting potential. Therefore, this database is essential for unravelling the seismotectonics of shallow earthquakes in volcanic areas, and contributes updating empirical scaling regressions that relate magnitude and extent of surface faulting.
RESUMEN
BACKGROUND: Targeting new molecular pathways leading to Osteoporosis (OP) and Osteoarthritis (OA) is a hot topic for drug discovery. Clusterin (CLU) is a glycoprotein involved in inflammation, proliferation, cell death, neoplastic disease, Alzheimer disease and aging. The present study focuses on the expression and the role of CLU in influencing the decrease of muscle mass and fiber senescence in OP-OA condition. METHODS: Vastus lateralis muscle biopsies were collected from 20 women with OP undergoing surgery for fragility hip fracture and 20 women undergoing arthroplasty for hip osteoarthritis. RESULTS: We found an overexpression of CLU in degenerated fibers in OP closely correlated with interleukin 6 (IL6) and histone H4 acetylation level. Conversely, in OA muscle tissues we observed a weak expression of CLU but no nuclear histone H4 acetylation. Ex vivo studies on isolated human myoblasts confirmed CLU overexpression in OP as compared to OA (p < 0.001). CLU treatment of isolated OP and OA myoblasts showed: modulation of proliferation, morphological changes, increase of histone H4 acetylation and induction of myogenin (MYOG) activation in OP myoblast only. In OP condition, functional knockdown of CLU by siRNA restores proliferative myoblasts capability and tissue damage repair, carried out by an evident upregulation of Transglutaminase 2 (TGM2). We also observed downmodulation of CX3CR1 expression with consequent impairing of the inflammatory infiltrate recruitment. CONCLUSIONS: Results obtained suggest a potential role of CLU in OP by influencing myoblasts terminal differentiation, epigenetic regulation of muscle cell differentiation and senescence. Moreover, CLU silencing points out its role in the modulation of tissue damage repair and inflammation, proposing it as a new diagnostic marker for muscle degeneration and a potential target for specific therapeutic intervention in OP related sarcopenia.
Asunto(s)
Clusterina/genética , Silenciador del Gen , Inflamación/patología , Mioblastos/metabolismo , Mioblastos/patología , Osteoporosis/metabolismo , Osteoporosis/patología , Acetilación/efectos de los fármacos , Adulto , Anciano , Anciano de 80 o más Años , Receptor 1 de Quimiocinas CX3C/metabolismo , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Clusterina/metabolismo , ADN/metabolismo , Femenino , Silenciador del Gen/efectos de los fármacos , Histonas/metabolismo , Humanos , Inflamación/complicaciones , Interleucina-6/metabolismo , Músculo Esquelético/metabolismo , Músculo Esquelético/patología , Mioblastos/efectos de los fármacos , Miogenina/metabolismo , Osteoartritis de la Cadera/metabolismo , Osteoartritis de la Cadera/patología , Osteoporosis/complicaciones , Proteínas Recombinantes/farmacologíaAsunto(s)
Anafilaxia/inducido químicamente , Antibacterianos/efectos adversos , Ceftriaxona/efectos adversos , Hipersensibilidad a las Drogas/etiología , Embolia Pulmonar/etiología , Tromboflebitis/tratamiento farmacológico , Anciano , Anafilaxia/inmunología , Anafilaxia/metabolismo , Hipersensibilidad a las Drogas/inmunología , Hipersensibilidad a las Drogas/metabolismo , Productos de Degradación de Fibrina-Fibrinógeno/metabolismo , Fibrinógeno/metabolismo , Humanos , Inmunoglobulina E/inmunología , Masculino , Embolia Pulmonar/diagnóstico por imagen , Embolia Pulmonar/metabolismo , Vena Safena/diagnóstico por imagen , Tromboflebitis/diagnóstico por imagen , Tomografía Computarizada por Rayos X , UltrasonografíaRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Anciano , Embolia Pulmonar/complicaciones , Embolia Pulmonar/diagnóstico , Anafilaxia/inducido químicamente , Ceftriaxona/efectos adversos , Hipersensibilidad a las Drogas/diagnóstico , Anafilaxia/complicaciones , Hipersensibilidad a las Drogas/terapia , Tromboflebitis/complicaciones , Factores de Riesgo , Enoxaparina/uso terapéutico , Acenocumarol/uso terapéutico , Vena Safena/patología , Vena SafenaRESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Anafilaxia/metabolismo , Anafilaxia/patología , Hipersensibilidad a las Drogas/genética , Pruebas Cutáneas/métodos , Presión Arterial/genética , Anafilaxia/genética , Anafilaxia/prevención & control , Hipersensibilidad a las Drogas/metabolismo , Pruebas Cutáneas/instrumentación , Presión Arterial/fisiologíaRESUMEN
No disponible
Asunto(s)
Femenino , Humanos , Persona de Mediana Edad , Anafilaxia/complicaciones , Hipersensibilidad Inmediata/complicaciones , Carmín/efectos adversos , Triptasas/análisis , Exposición Profesional/efectos adversosRESUMEN
BACKGROUND: Acute myocardial infarction (AMI), is related to a diffuse active inflammation of the coronary tree associated with rupture of one of the multiple vulnerable plaques. The presence of soluble mediators of inflammation with their synergic or antagonistic actions coordinates the physiological response determining the plaque fate and the fatal event. The present study focus on the cytokines network operating in human coronary plaques of patients died from AMI and controls, pointing out that coronaries of AMI patients produce PTX3 protein twice as that of controls and express high level of PTX3 mRNA. RESULTS: The presence of CX3CR1 polymorphisms is significantly correlated with the incidence and the outcome of acute myocardial infarction inducing in the whole coronary tree a strong recruitment of Th1 polarized inflammation that is directly correlated to PTX3 expression. CONCLUSIONS: Moreover we found a positive correlation between the expression of PTX3 in the plaque and the content of macrophage cells showing a M2 polarization indicating the possible role of this chemokine as mediator of immune response that would orchestrate plaque evolution and inflammatory cell type activation.
Asunto(s)
Proteína C-Reactiva/biosíntesis , Enfermedad de la Arteria Coronaria/metabolismo , Macrófagos/metabolismo , Placa Aterosclerótica/metabolismo , Componente Amiloide P Sérico/biosíntesis , Anciano , Anciano de 80 o más Años , Enfermedad de la Arteria Coronaria/patología , Femenino , Humanos , Macrófagos/patología , Masculino , Persona de Mediana Edad , Placa Aterosclerótica/patologíaRESUMEN
Fractalkine is a proinflammatory chemokine that participates in atherosclerotic process mediating the interactions of vascular cells and leukocytes and selective recruitment of Th1 lymphocytes, through interaction with CX3CR1 receptor. The polymorphism of the fractalkine receptor 280M-containing haplotype, which codifies for a receptor with minor expression and with a reduced binding capability, represents a novel protective factor of atherosclerotic disease. We investigated the association among CX3CR1 genotype, the inflammatory infiltrate subpopulations recruited in the plaque, and the in situ expression of fractalkine and its receptor, in patients who died of myocardial infarction (AMI) compared with subjects who died of noncardiac causes. Patients with nonlethal AMI (AMI survivors) were also investigated to correlate the CX3CR1 polymorphisms and the incidence of lethal AMI. A strong T cells infiltrate was found in infarct related artery (IRA) plaques of AMI patients presenting the V249 T280 haplotype (84%). Conversely, a decreased T cell recruitment was associated with I249T280 haplotype in the controls (64%). The significant higher presence of the variant allele I249 in homo- and heterozygosis, found in controls (91%) and in AMI survivors (94%), with respect to the patients who died of AMI (48%), showed the relevance of this polymorphism both in the onset and outcome of acute myocardial infarction. The presence of CX3CR1 polymorphisms could influence the incidence and the outcome of acute myocardial infarction, altering the inflammation of the whole coronary tree by the impaired recruitment of Th1 polarized subpopulation in the coronary plaque.
Asunto(s)
Aterosclerosis/genética , Quimiocina CX3CL1/genética , Infarto del Miocardio/genética , Receptores de Quimiocina/genética , Anciano , Aterosclerosis/mortalidad , Aterosclerosis/patología , Autopsia , Receptor 1 de Quimiocinas CX3C , Quimiocina CX3CL1/metabolismo , Femenino , Estudios de Asociación Genética , Predisposición Genética a la Enfermedad , Genotipo , Haplotipos , Humanos , Inflamación/genética , Inflamación/patología , Masculino , Infarto del Miocardio/mortalidad , Infarto del Miocardio/fisiopatología , Polimorfismo de Nucleótido Simple , Receptores de Quimiocina/metabolismo , Células TH1/metabolismo , Células TH1/patologíaRESUMEN
In this study we investigated total and hexavalent chromium removal in an h-SSF constructed wetland (CW) planted with Phragmites australis and operating as post-treatment of effluent wastewater from an activated sludge plant serving the textile industrial district of Prato (Italy). Two measurement campaigns were carried out in 2006 and 2008-2010 in which more than 950 inlet and outlet samples were analyzed. When inlet and outlet concentrations were compared one to the other, the latter were found to be significantly lower than the former (p < 0.001); during the entire period of investigation, removal of hexavalent chromium equal to about 70% was achieved. Outlet concentrations ranged between values lower than the quantification limit (0.5 microg L(-1)) and 4.5 microg L(-1), and in all cases were therefore lower than the limit indicated for hexavalent chromium in the Italian regulation for water reuse (5 microg L(-1)). The comparison of the removal efficiencies achieved for hexavalent and trivalent chromium during the two campaigns suggested that the removal of the former can be sustained in the long term, while for the latter, the treatment efficiency is more sensitive to the age of the CW, being that it is it based on trivalent chromium retention in the reed bed.
Asunto(s)
Cromo/aislamiento & purificación , Residuos Industriales , Industria Textil , Contaminantes Químicos del Agua/aislamiento & purificación , Humedales , Límite de Detección , Control de CalidadRESUMEN
Growth factors and their respective receptors are key regulators in development and homeostasis of the nervous system, and changes in the function, expression, or downstream signaling of growth factors are involved in many neuropathological disorders. Recently, research has yielded a rich harvest of information about molecules and gene, and currently the assumption "a gene-a protein", where each gene encodes the structure of a single protein, is becoming a paradox. In the past years, the discovery of synergic or antagonistic proteins deriving from the same gene is a novelty upsetting. In some way, the conventional function of proteins involved in DNA repair, cell death/growth induction, vascularization, and metabolism is inhibited or shifted toward other pathways by soluble mediators that orchestrate such change depending on the microenvironment conditions. In this chapter, we focus on the antithetic properties that proteins could exert, depending on the microenvironment that orchestrates the complex networks among proteins and their respective partners.
Asunto(s)
Clusterina/metabolismo , Interleucina-6/metabolismo , Fármacos Neuroprotectores/metabolismo , Isoformas de Proteínas/metabolismo , Transducción de Señal/fisiología , Factor A de Crecimiento Endotelial Vascular/metabolismo , Animales , Encéfalo/citología , Encéfalo/metabolismo , Clusterina/genética , Células Endoteliales/fisiología , Glaucoma/patología , Glaucoma/fisiopatología , Homeostasis , Humanos , Interleucina-6/genética , Neovascularización Fisiológica , Neuronas/fisiología , Isoformas de Proteínas/genética , Receptores de Factores de Crecimiento Endotelial Vascular/metabolismo , Factor A de Crecimiento Endotelial Vascular/genéticaRESUMEN
Allergic disorders are viewed generally as organ diseases and thus referred to organ specialists, such as the ear, nose and throat specialist for rhinitis, the pulmonologist for asthma, the dermatologist for dermatitis, and so on. Indeed, the systemic nature of allergy is made evident by the fact that the same individual may develop during the life different manifestations to a given allergen. This is true for example in sensitisation to house dust mites, which may start in childhood as atopic dermatitis and later express as asthma or rhinitis. The major player in driving the immune response is the T lymphocyte, and the T helper subpopulations--Th1 and Th2--as well as the T regulatory cells, are involved in orienting tolerance or reactivity to allergens. Interesting observations on the systemic or organ-specific actions of T cells were obtained by transplantations from allergic donors to non-allergic recipients. Bone marrow is able to transfer all allergic manifestations, while lung transplantation transfers only asthma. A number of factors are involved in the expression of allergy as a systemic or organ disease and deserve deeper investigations. They include the antigen presenting cells, the homing of T cells, the cytokine and chemokine pattern, and the adhesion molecules.
Asunto(s)
Alérgenos/inmunología , Citocinas/inmunología , Hipersensibilidad/inmunología , Linfocitos T Reguladores/inmunología , Animales , Quimiotaxis de Leucocito , Humanos , Pulmón/inmunología , Piel/inmunología , Células TH1/inmunología , Células Th2/inmunologíaRESUMEN
Allergic skin disorders include urticaria, angioedema, contact dermatitis and atopic dermatitis, but the model fitting most closely the systemic concept of allergy is atopic dermatitis (AD), the pathogenesis of which is linked to a complex interaction between skin barrier dysfunction and environmental factors such as allergens and microbes. In particular, an important advance was the demonstration that the mutation of the skin barrier protein filaggrin is related strictly to allergen sensitization and to the development of asthma in subjects with AD. The altered skin barrier function, caused by several factors, results in the passage of allergens through the skin and to systemic responses. A pivotal role in such a response is exerted by Langerhans cells which, via their immunoglobulin E (IgE) receptor, capture the allergens and present them to T cells. When T helper type 2 (Th2) cells are activated, the production of a proinflammatory cytokines and chemokines pattern sustains the persistence of inflammation. Known AD-related cytokines are interleukin (IL)-5, IL-13 and tumour necrosis factor (TNF)-alpha, with emerging importance for IL-17, which seems to drive airway inflammation following cutaneous exposure to antigens, and IL-31, which is expressed primarily in skin-homing Th2 cells. Skin-homing is another crucial event in AD, mediated by the cutaneous lymphocyte-associated antigens (CLA) receptor, which characterizes T cell subpopulations with different roles in AD and asthma.
Asunto(s)
Dermatitis Atópica/inmunología , Hipersensibilidad/inmunología , Piel/inmunología , Alérgenos/inmunología , Animales , Citocinas/inmunología , Proteínas Filagrina , Humanos , Inmunoglobulina E/inmunología , Proteínas de Filamentos Intermediarios/metabolismo , Células de Langerhans/inmunología , Células Th2/inmunologíaRESUMEN
The current burden of allergic diseases, estimated by both direct and indirect costs, is very relevant. In fact the cost estimation for rhinitis amount globally to 4-10 billion dollars/year in the U.S. and to an average annual cost of 1089 euros per child/adolescent and 1543 euros per adult in Europe. The estimated annual costs in Northern America for asthma amounted to 14 billion dollars. Consequently, preventive strategies aimed at reducing the clinical severity of allergy are potentially able to reduce its costs. Among them, specific immunotherapy (SIT) joins to the preventive capacity the carryover effect once treatment is discontinued. A number of studies, mainly conducted in the US and Germany demonstrated a favourable cost-benefit balance. In the nineties, most surveys on patients with allergic rhinitis and asthma reported significant reductions of the direct and indirect costs in subjects treated with SIT compared to those treated with symptomatic drugs. This is fully confirmed in recent studies conducted in European countries: in Denmark the direct cost per patient/year of the standard care was more than halved following SIT; in Italy a study on Parietaria allergic patients demonstrated a significant difference in favor of SIT plus drug treatment for three years versus drug treatment alone, with a cost reduction starting from the 2nd year and increasing to 48% at the 3rd year, with a highly statistical significance which was maintained up to the 6th year, i.e. 3 years after stopping immunotherapy, corresponding to a net saving for each patient at the final evaluation of 623 euros per year; in France a cost/efficacy analysis comparing SIT and current symptomatic treatment in adults and children with dust mite and pollen allergy showed remarkable savings with SIT for both allergies in adults and children.
Asunto(s)
Costo de Enfermedad , Desensibilización Inmunológica/economía , Economía Farmacéutica , Hipersensibilidad Respiratoria/economía , Hipersensibilidad Respiratoria/terapia , Adolescente , Adulto , Niño , Preescolar , Análisis Costo-Beneficio , Desensibilización Inmunológica/normas , Economía Farmacéutica/organización & administración , Economía Farmacéutica/tendencias , Europa (Continente) , Costos de la Atención en Salud , Gastos en Salud , Humanos , Inyecciones Subcutáneas , Persona de Mediana Edad , Estados UnidosRESUMEN
Allergic rhinitis and asthma constitute a global health problem because of their very high prevalence and the consequent burden of disease, concerning medical and economical issues. Among the treatments of allergy, specific immunotherapy has the capacity to favourably alter the natural history of the disease both during and after its performance and thus to reduce the direct and indirect costs of allergic rhinitis and asthma. A number of studies reported such cost reduction for traditional, subcutaneous immunotherapy and recent data demonstrate that also sublingual immunotherapy (SLIT) is associated to economic advantages and/or monetary savings, specifically in terms of reduction of disease economic burden. Only few formal economic assessments of SLIT have been carried out so far, this article will present and discuss the published studies addressed to this issue. The data obtained, although the number of studies is still limited, provide preliminary evidence supporting a SLIT effect on sparing costs for respiratory allergy.